annb0t
Top 20
Immutep Limited
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (âeftiâ) and avelumab (BAVENCIO®) Expansion into urothelial cancer builds on core strategy to increase target indications for combination approaches with efti to exploit the full potential of this unique LAG-3 candidate First patient is expected to be enrolled and dosed in H1 of calendar year 2023
...
>>> Read more: Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (âeftiâ) and avelumab (BAVENCIO®) Expansion into urothelial cancer builds on core strategy to increase target indications for combination approaches with efti to exploit the full potential of this unique LAG-3 candidate First patient is expected to be enrolled and dosed in H1 of calendar year 2023
...
>>> Read more: Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
